Prime Medicine, Inc. (PRME) stock
PRMENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.84+0.02 (+0.52%)
Close on Nov 19, 2026Market cap $696.49MP/E –Yield –
Prime Medicine free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Prime Medicine's free cash flow for the twelve months ending Jun 30, 2026 was -$156.85M. For fiscal 2025 it was -$167.10M. The highest annual figure on record is -$6.18M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$167.10M | – |
| FY2024 | Dec 31, 2024 | -$130.16M | – |
| FY2023 | Dec 31, 2023 | -$174.14M | – |
| FY2022 | Dec 31, 2022 | -$147.92M | – |
| FY2021 | Dec 31, 2021 | -$38.23M | – |
| FY2020 | Dec 31, 2020 | -$6.18M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$41.09M | – |
| Q1 FY2026 | Mar 31, 2026 | -$42.92M | – |
| Q4 FY2025 | Dec 31, 2025 | -$37.55M | -359.8% |
| Q3 FY2025 | Sep 30, 2025 | -$35.29M | – |
| Q2 FY2025 | Jun 30, 2025 | -$42.98M | – |
| Q1 FY2025 | Mar 31, 2025 | -$51.28M | – |
| Q4 FY2024 | Dec 31, 2024 | $14.45M | – |
| Q3 FY2024 | Sep 30, 2024 | -$27.19M | – |
| Q2 FY2024 | Jun 30, 2024 | -$47.39M | – |
| Q1 FY2024 | Mar 31, 2024 | -$70.03M | – |
| Q4 FY2023 | Dec 31, 2023 | -$45.70M | – |
| Q3 FY2023 | Sep 30, 2023 | -$42.08M | – |
| Q2 FY2023 | Jun 30, 2023 | -$42.80M | – |
| Q1 FY2023 | Mar 31, 2023 | -$43.56M | – |
| Q4 FY2022 | Dec 31, 2022 | -$35.53M | – |
| Q3 FY2022 | Sep 30, 2022 | -$34.89M | – |
| Q2 FY2022 | Jun 30, 2022 | -$25.03M | – |
| Q1 FY2022 | Mar 31, 2022 | -$52.48M | – |
| Q4 FY2021 | Dec 31, 2021 | -$13.57M | – |
See a number that looks wrong?